Lymphoma and CLL   |   Breast Cancer   |   Multiple Myeloma   |   Melanoma   |   RCC   |   Industry

Andrew Zelenetz, MD, PhD

Vice Chair, Department of Medicine

Professor of Medicine, Weill-Cornell Medical College

Andrew D. Zelenetz, MD, PhD is the Vice Chair, Medical Informatics in the Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York. Prior to that, he had held the position of Chief, Lymphoma Service in the Division of Hematology/Oncology at MSKCC from 1994-January, 2013. He is also Professor of Medicine at Weill Medical College of Cornell University.
He has helped develop a number of the agents now approved to treat lymphoma — including 131I-tosituomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies he is evaluating the benefits of novel combinations of agents. In another area of research he is working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. He has published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology and Clinical Cancer Research.
Dr. Zelenetz received his BA from Harvard College, his PhD from Harvard University’s Graduate School of Arts and Sciences, Division of Medical Sciences and his MD from Harvard Medical School. Both his internship and residency in medicine were completed at Stanford University Medical Center as well as a clinical fellowship and research fellowship in oncology.
Dr. Zelenetz is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American College of Physicians. He participates in various committees: he is Vice Chairperson of the Cancer and Leukemia Group B Lymphoma Core Committee, Chair of the NCCN Non-Hodgkin’s Lymphoma Panel, Board Member of the Leukemia and Lymphoma Society and member of the Lymphoma Research Foundation Scientific Advisory Board. He has been the recipient of the Memorial Sloan Kettering Fellowship Teaching Excellence Award multiple times and has received the Rodger Winn Award from the National Comprehensive Cancer Network in 2012.

Managing Diffuse Large B-cell Lymphoma (DLBCL): A Case-based Approach to Treatment Selection

Evaluating New & Emerging Treatment Options for Non-Hodgkin Lymphoma (NHL)

Andre Goy, MD, MS

Chairman and Director and Chief of Lymphoma

John Theurer Cancer Center, at Hackensack University Medical Center

Andre Goy, M.D., M.S., is an internationally renowned clinician and researcher of all types of lymphoma, including Hodgkin’s disease, non-Hodgkin’s lymphoma, and HIV-associated lymphoma. As chief of John Theurer Cancer Center’s Division of Lymphoma, he leads New Jersey’s largest program for research, treatment and management of lymphoma. Dr. Goy has trained and/or worked at some of the world’s leading medical institutions, including Memorial Sloan-Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris and The Pasteur Institute.
Dr. Goy was instrumental in developing the John Theurer Cancer Center’s Tissue Bank, where samples of cells, tissue, and other anatomical structures are stored and analyzed for research purposes. The Tumor Bank has received more than 1,600 patient consents since it launched.
Dr. Goy is widely-known for his work showing the first evidence of activity of bortezomib in mantle cell lymphoma and then as co-principal investigator on the PINNACLE trial, which led to the Food & Drug Administration’s approval of VELCADE® (bortezomib) for relapsed / refractory mantle cell lymphoma patients in 2006. He also took part in the original pilot study for RITUXAN® (rituximab), which has been widely used to treat lymphomas, leukemias, and autoimmune disorders.
Dr. Goy’s research centers on developing novel targeted therapies for lymphoma and developing biomarkers for lymphoma. He has been invited to speak and teach around the world, and his research has been published extensively. He is a journal reviewer for eight medical publications that include: Blood, Clinical Cancer Research and the Journal of Clinical Oncology.

Managing Diffuse Large B-cell Lymphoma (DLBCL): A Case-based Approach to Treatment Selection

Evaluating New & Emerging Treatment Options for Non-Hodgkin Lymphoma (NHL)

Kenneth Anderson, MD

Kraft Family Professor of Medicine

Harvard Medical School

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at John’s Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in it is microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome. He is the recipient of many scientific and humanitarian awards including the International Myeloma Workshop Waldenstrom’s Award in 2003, the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2005, the American Association for Cancer Research Joseph H. Burchenal Award in 2007, and the American Society of Hematology William Dameshek Prize in 2008. He was elected into the Johns Hopkins Society of Scholars in 2009, the Institute of Medicine of the National Academy of Sciences in 2010, and the Royal College of Physicians and of Pathologists (UK) in 2010. In 2011 he received the American Society of Clinical Oncology David A. Karnofsky Award and the Hope Funds for Cancer Research Award of Excellence in Clinical Research, and in 2012 received the Ron Burton Humanitarian Award, the Harvard Medical School Warren Alpert Foundation Prize, and the American Cancer Society Medal of Honor.

Integrating New Therapies into the Treatment of Newly Diagnosed MM

Controversies in the Management of Relapsed/Refractory MM

Philip McCarthy, MD

Professor of Oncology

Roswell Park Cancer Institute

Dr. McCarthy is the Director of the Blood and Marrow Transplantation (BMT) Program at Roswell Park Cancer Institute (RPCI) and a Professor of Oncology. Dr. McCarthy has been a BMT Physician and Hematologist/Oncologist since finishing fellowship training in 1989. He has been the BMT Director at RPCI since 1997. He is a member of the Cancer and Leukemia Group B (CALGB) cooperative clinical trials group, the Center for Institutional Research on Blood and Marrow Transplantation (CIBMTR) as well as a member of the editorial boards of two BMT journals. He has been a clinical investigator in oncology, particular BMT, for more than 20 years. He has served as chair, or co-chair, of several clinical trials, including CALGB 100104, a phase III clinical trial evaluating lenalidomide maintenance after autologous hematopoietic cell transplant (HCT) for multiple myeloma. He is a member of the protocol team for the ongoing BMT Clinical Trials Network (CTN) study: A Trial Single Autologous Transplant with or without RVD Consolidation versus Tandem Transplant and Maintenance Therapy for Patients with Multiple Myeloma. Dr. McCarthy is a member of the American Society of Hematology and the American Society of Clinical Oncology. His research interests are devoted to developing novel myeloablative and non-myeloablative autologous and allogeneic BMT treatments of hematologic disorders that will lead to improved patient outcomes and decreased toxicity.

Integrating New Therapies into the Treatment of Newly Diagnosed MM

Controversies in the Management of Relapsed/Refractory MM

Michael A. Davies, MD, PhD

Associate Professor, Department of Melanoma Medical Oncology

MD Anderson Cancer Center

Dr. Davies earned his medical and doctorate degrees from the University of Texas Health Science Center in Houston. He completed his clinical residency training in internal medicine at the Massachusetts General Hospital, and his medical oncology fellowship at the University of Texas MD Anderson Cancer Center. Dr. Davies is currently an associate professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, with a joint appointment in the Department of Systems Biology. Dr. Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of protein kinase signaling pathways in cancer. Dr. Davies has made several key insights in the role of the PI3K-AKT pathway in melanoma, including the identification of disease-specific mutations in AKT isoforms, differential activation of the pathway in different metastatic sites, and compensatory pathway activation as a mechanism of resistance to MAPK pathway inhibitors. Dr. Davies has led or co-led several clinical trials, including the testing of targeted therapies in patients with brain metastases from melanoma. Dr. Davies has published peer-reviewed articles in a variety of journals, including Cancer Cell, Lancet Oncology, Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, and Cancer. He is the principal investigator of R01 grants from NCI and the Cancer Prevention Research Institute of Texas; Young Investigator and Career Development Awards from American Society for Clinical Oncology (ASCO); and he is the multi-center PI of a 2013 Team Science Grant from the Melanoma Research Foundation (MRA). Dr. Davies is a member of the Melanoma Research Foundation Breakthrough Consortium, and the co-director of the MD Anderson Melanoma Moon Shot Team and the MD Anderson

Targeted Therapy in Melanoma

Sumanta Kumar Pal, MD

Assistant Professor, Department of Medical Oncology & Therapeutics Research

City of Hope

Sumanta Kumar Pal, M.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope. Having been appointed to the faculty for just over four years, Dr. Pal has been extremely productive, publishing more than 85 manuscripts in peer-reviewed journals. He has presented his work in multiple international meetings. Dr. Pal began his college career at the age of 13 through the California State University, Los Angeles Early Entrance Program. He began medical school at the age of 17 at the University of California, Los Angeles (UCLA), where he developed an immediate interest in cancer research. Working in the laboratory of Dennis Slamon, M.D., Ph.D., Dr. Pal examined the breast cancer drug trastuzumab, performing laboratory-based studies to elucidate mechanisms of resistance to the agent. He continued this work during the course of his residency training at UCLA.
After completing his residency, Dr. Pal transitioned to City of Hope where he trained under Robert Figlin, M.D., developing clinical trials and translational studies for genitourinary cancer, principally in the domain of renal cell carcinoma and prostate cancer. He has garnered numerous awards to support his work, including grants from the California Breast Cancer Research Program, the National Comprehensive Cancer Network and the National Institutes of Health. He recently received a Young Investigator Award from the Kidney Cancer Association to recognize his outstanding research in this domain, and further received the 2012 Charles A. Coltman Translational Research Award from the Southwest Oncology Group to support his work in bladder cancer.
Dr. Pal’s vision is to take discoveries made in the laboratory and translate these findings as quickly and efficiently as possible into tangible benefits for patients.

Strategies for Minimizing Toxicities in Patients Undergoing Treatment for RCC

Judd W Moul, MD

Director, Duke Prostate Center

Duke University Medical Center

Dr Judd W. Moul is Professor and Chief of the Division of Urologic Surgery and Director of the Duke Prostate Center at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, and an attending Urologic Oncologist at the Walter Reed Army Medical Center (WRAMC) in Washington, DC. In addition, he was Director of the Center for Prostate Disease Research, a Congress-mandated research program of the Department of Defense based at USUHS and WRAMC. Dr Moul completed his Urologic Oncology Fellowship at Duke University and graduated summa cum laude from Pennsylvania State University. He earned his medical degree from Jefferson Medical College.
Dr Moul currently serves on the editorial boards of Urology, Brazilian Journal of Urology, and World Journal of Robotic Surgery, and is Co-Editor of Prostate Cancer and Prostatic Diseases. He has published over 500 medical and scientific manuscripts and book chapters and has lectured at national and international meetings.
Honors received have included the 1995 American Medical Association Young Physicians Section Community Service Award for his national involvement in prostate cancer patient support groups, the 1996 Sir Henry Welcome Research Medal and Prize from the Association of Military Surgeons of the United States, and selection as a 1994 Fellow for the American Urological Association/European Association of Urology International Academic Exchange Program. In 2006, Dr. Moul was selected as Chairman of the newly founded American Urological Association Foundation Education Council.

Forgot Password Click Here to Register